AI-empowered drug discovery.
Pangea Bio discovers and develops novel medicines to treat neurological and neuropsychiatric disorders. We deploy AI to uncover promising molecules from nature’s diverse chemical space, enhanced by traditional human evidence of safety and efficacy.
Pushing for a better tomorrow.
80%
Nature has co-evolved alongside human biology, resulting in a vast reservoir of untapped therapeutic compounds, with prior human medicinal use as an indicator of the efficacy and tolerability of the underlying chemistry.
57+ Mn
... with an expected growth to over 150 Mn by 2050. This example of growing patient populations in CNS disorders shows the urgent need for new treatments addressing neurological and neuro-psychiatric diseases.
84%
The vast majority of CNS small molecules are nature-inspired, showing the great potential the natural world offers to uncover novel CNS drugs.
<1%
Nature is one of the richest untapped sources of possible therapeutic compounds. Recent technological and biological advances now allow us to investigate the potential of the 99% unexplored small molecules for CNS disorders and study the natural world at scale.
We combine nature-inspired Central Nervous System (CNS) drug development with AI to build a highly scaleable NCE pipeline for a range or CNS disorders. Our lead asset OT-003, inspired by a natural compound, shows compelling efficacy across neurological disease models and we are planning to start our Phase 1 studies in 2024.
We send our newsletter regularly, sharing news and trends around Pangea and our research space.
